Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bristol-Myers Squibb | INDUSTRY |
| Yale University | OTHER |
Not provided
Not provided
Not provided
Not provided
A thorough discussion of treatment options to manage inflammatory bowel disease (IBD), including the risks and benefits of each class of medication, can be a complex discussion and time consuming. Having to use a translator adds an additional layer of time and complexity to these discussions as well as potential misunderstanding. Further, in addition to language, cultural differences can also play into treatment acceptance.
This study aims to determine the impact of primary language on the selection of treatment for IBD and on disease outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| English as primary language |
| ||
| Non-English as primary language |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NO INTERVENTION | Other | NO INTERVENTION - OBSERVATIONAL ONLY |
|
| Measure | Description | Time Frame |
|---|---|---|
| Current use of advanced therapy | Use of or prescription of a biologic or small molecule therapy to treat inflammatory bowel disease | baseline |
| Measure | Description | Time Frame |
|---|---|---|
| IBD-related disease complications | 6 months | |
| IBD-related disease complications | 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Our target population will include adult subjects (ages 18 and older) with confirmed IBD who do and do not identify English as their primary language. These subjects will be either new or returning patients seen in the outpatient clinics at either the Yale New Haven Hospital system or the University of Texas at Austin affiliated hospitals or clinics. Men and women and persons of all races and ethnicities will be encouraged to participate in an equal basis.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Linda A Feagins, MD | Contact | 512-324-7831 | linda.feagins@austin.utexas.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dell Medical School at the University of Texas at Austin | Austin | Texas | 78712 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| ID | Term |
|---|---|
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D007410 | Intestinal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided